Merck stops production of osteoporosis drug over stroke concerns, has yet to stop vaccine production

Pharmaceutical giant Merck announced on September 2 that it is abandoning plans for a new osteoporosis drug known as odanacatib, after the latest phase of safety trials showed that the drug significantly raised patients’ risk of stroke. The findings of that trial will be presented at the conference of the American Society for Bone Mineral Research.

Read more here: Merck stops production of osteoporosis drug over stroke concerns, has yet to stop vaccine production – NaturalNews.com

Please follow and like us:

Related Post

Leave a Reply